ERBB2 and metabolic syndrome: MetS status was not associated with clinical T stage, N stage, hormone receptors, HER2 status or p53 status, and no differences in the number of NAC dose reductions and treatment interruptions were noted between the two groups (all P>0.05) (Table 1).